Extended Data Fig. 1: DYRK3 interactions are differentially regulated upon GSK-626616 treatment. | Nature

Extended Data Fig. 1: DYRK3 interactions are differentially regulated upon GSK-626616 treatment.

From: Kinase-controlled phase transition of membraneless organelles in mitosis

Extended Data Fig. 1

a, Experimental design of the SILAC quantitative pull-down assays to identify protein–protein interaction partners of DYRK3. b, Experimental design of triple-SILAC quantitative pull-down assays to identify change of DYRK3 interactors upon GSK-626616 inhibitor treatment. c, Scatter plot shows change in DYRK3 interactors upon GSK-626616 inhibitor treatment (normalized heavy labelled/medium labelled log2 ratios). Only proteins detected as DYRK3-specific interactors (normalized heavy labelled (H)/light labelled (L) or medium labelled (M)/light labelled log2 ratio >1) were retained on this plot. Interactors are considered differentially regulated (coloured rims) if the heavy labelled/medium labelled log2 ratio is greater than 1 or less than −1. d, Mean intensity of DYRK3 interactors upon GSK-626616 inhibitor treatment. Data are representative of two technical replicates. e, Protein abundance of DYRK3 interactors and DYRK3 upon GSK-626616 inhibitor treatment. Data are representative of two independent experiments. Box plots: centre line, median; box, interquartile range; whiskers, 1.5× interquartile range; dots, outliers.